ADMA vs NBIX · P/E 22, rev $238.9M vs P/E 45, rev $1.77B
ADMA Biologics Inc (ADMA) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
ADMA Biologics Inc (ADMA) is a biotechnology company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ADMA revenue for 2026-06-30 was $238.9M. Net income was $83.2M. ADMA currently screens at market cap $4.39B and trailing P/E 21.9.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
ADMA currently screens at market cap $4.39B and trailing P/E 21.9. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the ADMA and NBIX stock pages for the full models.
Not investment advice.